Aspirin To Target Arterial Events In Chronic Kidney Disease (ATTACK)
Research type
Research Study
Full title
Aspirin To Target Arterial events in Chronic Kidney Disease
IRAS ID
228831
Contact name
Letitia Baldock
Contact email
Sponsor organisation
University of Southampton
Eudract number
2018-000644-26
Duration of Study in the UK
7 years, 5 months, 30 days
Research summary
This study aims to find out whether people with chronic kidney disease (CKD) should take daily low-dose aspirin to reduce the risk of a first heart attack or stroke (cardiovascular disease, CVD).
CKD is a term used by doctors when the kidneys are not working as well as they should. It is very common and affects as many as one in eight adults in the UK. CKD is important because it is linked to a much higher chance of CVD.
CVD is usually caused by small blood clots. Aspirin thins the blood so reduces the chance that clots will form but also increases the chances of bleeding. Studies in people with previous CVD show that aspirin reduces the risk of further heart attacks and strokes, and that these benefits are much greater than the risks of bleeding. As a result, aspirin is recommended for people (both with CKD and without CKD) who already have CVD.
Here we want to determine whether aspirin should be given to people with CKD to prevent a first heart attack or stroke (primary prevention). As CVD is more common in people with CKD than in the general population we would expect aspirin to be of greater benefit, but the risks of bleeding may also be higher. Before we can recommend aspirin for primary prevention in people with CKD we need to be sure that the benefits outweigh the possible risks. The National Institute of Health and Care Excellence (NICE) therefore recommended that a definitive research study was needed.
The study will recruit adults with CKD and no previous CVD via their GP practices. Eligible patients will be allocated to receive aspirin or not. We will follow patients up for several years (electronically/questionnaires) to determine whether aspirin should be prescribed to this population in the future.
REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
18/EM/0248
Date of REC Opinion
9 Oct 2018
REC opinion
Further Information Favourable Opinion